METTL14 and renal cell carcinoma: Taken together, these results indicate that m6A modification and METTL14 expression are significantly lower in metastatic RCC tumors than in primary tissues, and METTL14 possesses the potential to be an independent biomarker for predicting prognosis and metastasis in RCC.